Pipeline

December 15, 2019

Company	Drug/Device	Medical Condition	Status
Nouscom	NOUS-209	cancer	Phase 1 trial initiated in subjects with microsatellite instable high gastric, colorectal and gastro-esophageal junction cancers in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab at multiple centers in the U.S.
EicOsis LLC	EC5026	pain management	Phase 1a trial initiated enrolling healthy subjects
Oncternal Therapeutics	TK216	Ewing Sarcoma	Phase 1b expansion cohort initiated enrolling 18 subjects with relapsed or refractory Ewing Sarcoma at seven sites across the U.S.
Helix Biopharma	L-DOS47	advanced pancreatic cancer	Phase 1b/2 trial initiated in 20 subjects with advanced pancreatic cancer at the HonorHealth Scottsdale Osborn Medical Center in Scottsdale, Arizona
ProQR	QR-1123	autosomal dominant retinitis pigmentosa	Phase 1/2 trial initiated enrolling 35 subjects with autosomal dominant retinitis pigmentosa at sites in North America
Rocket Pharmaceuticals	RP-L102	Fanconi Anemia	Phase 2 trial initiated in 12 pediatric subjects with Fanconi Anemia at Lucile Packard Children’s Hospital Stanford and Hospital Infantil Universitario Niño Jesús
ImaginAb	89Zr-Df-IAB22M2C	cancer and immune system imaging	Phase 2 trial initiated enrolling subjects with advanced and metastatic cancer at Penn Medicine in Philadelphia, Pa.
Viela Bio	VIB4920	Sjögren’s syndrome	Phase 2b trial initiated enrolling subjects with Sjögren’s syndrome
Tonix Pharmaceuticals	TNX-102 SL	fibromyalgia	Phase 3 trial initiated enrolling 470 subjects at 40 U.S. sites
Ocugen	OCU300	ocular graft versus host disease	Phase 3 trial initiated enrolling 60 subjects with ocular graft versus host disease
Eli Lilly	LOXO-292	non-small cell lung cancer	Phase 3 trial initiated enrolling 400 subjects
CStone Pharmaceuticals	avapritinib	advanced gastrointestinal stromal tumors	Phase 3 trial initiated enrolling subjects with advanced gastrointestinal stromal tumors in China
Can-Fite Biopharma	Piclidenoson	moderate to severe plaque psoriasis	Phase 3 trial initiated enrolling 407 subjects with moderate to severe plaque psoriasis in Europe, Israel and Canada
InMed Pharmaceuticals	INM-755	epidermolysis bullosa	Clinical Trial Authorization acceptance granted by the MHRA
CStone Pharmaceuticals	CS3005	cancer	Clinical Trial Authorization acceptance granted by the TGA
STAAR Surgical	EVO/EVO+ VISIAN Toric Implantable Collamer Lens	myopia with astigmatism	IDE approval granted by the FDA
Abeona Therapeutics	EB-101	recessive dystrophic epidermolysis bullosa	IND approval granted by the FDA
CSL Behring	Hizentra	chronic inflammatory demyelinating polyneuropathy	Orphan drug designation granted by FDA
VistaGen Therapeutics	PH94B neuroactive nasal spray	social anxiety disorder	Fast Track Designation granted by the FDA
Dermira	lebrikizumab	moderate-to-severe atopic dermatitis	Fast Track Designation granted by the FDA
Equillium	itolizumab	lupus nephritis	Fast Track Designation granted by the FDA
Sarepta Therapeutics	Vyondys 53	duchenne muscular dystrophy	Accelerated approval granted by the FDA
OrthoGrid Systems	PhantomMSK Trauma	imaging for orthopedic surgery	510(k) Clearance granted by the FDA
TechMah Medical LimaCorporate	Smart SPACE Shoulder 3D Planner & 3D Positioner	3D pre-operative planning and 3D positioners for intra-operative positioning	510(k) Clearance granted by the FDA
etectRx	ID-Cap	ingestible event marker	Clearance granted by the FDA
AptarGroup	Unidose Liquid System	acute repetitive seizures	Clearance granted by the FDA
Dyve Biosciences	DYV-700	acute gout pain	Approval granted by the FDA
Meitheal Pharmaceuticals	Enoxaparin Sodium Injection, USP	preventing blood clots	Approval granted by the FDA
Amgen	AVSOLA	moderate-to-severe rheumatoid arthritis	Approval granted by the FDA